Literature DB >> 31487061

EZH2 Supports Osteoclast Differentiation and Bone Resorption Via Epigenetic and Cytoplasmic Targets.

Juraj Adamik1, Sree H Pulugulla2, Peng Zhang1, Quanhong Sun1, Konstantinos Lontos1, David A Macar2, Philip E Auron2, Deborah L Galson1,3.   

Abstract

Key osteoclast (OCL) regulatory gene promoters in bone marrow-derived monocytes harbor bivalent histone modifications that combine activating Histone 3 lysine 4 tri-methyl (H3K4me3) and repressive H3K27me3 marks, which upon RANKL stimulation resolve into repressive or activating architecture. Enhancer of zeste homologue 2 (EZH2) is the histone methyltransferase component of the polycomb repressive complex 2, which catalyzes H3K27me3 modifications. Immunofluorescence microscopy reveals that EZH2 localization during murine osteoclastogenesis is dynamically regulated. Using EZH2 knockdown and small molecule EZH2 inhibitor GSK126, we show that EZH2 plays a critical epigenetic role in OCL precursors (OCLp) during the first 24 hours of RANKL activation. RANKL triggers EZH2 translocation into the nucleus where it represses OCL-negative regulators MafB, Irf8, and Arg1. Consistent with its cytoplasmic localization in OCLp, EZH2 methyltransferase activity is required during early RANKL signaling for phosphorylation of AKT, resulting in downstream activation of the mTOR complex, which is essential for induction of OCL differentiation. Inhibition of RANKL-induced pmTOR-pS6RP signaling by GSK126 altered the translation ratio of the C/EBPβ-LAP and C/EBPβ-LIP isoforms and reduced nuclear translocation of the inhibitory C/EBPβ-LIP, which is necessary for transcriptional repression of the OCL negative-regulatory transcription factor MafB. EZH2 in multinucleated OCL is primarily cytoplasmic and mature OCL cultured on bone segments in the presence of GSK126 exhibit defective cytoskeletal architecture and reduced resorptive activity. Here we present new evidence that EZH2 plays epigenetic and cytoplasmic roles during OCL differentiation by suppressing MafB transcription and regulating early phases of PI3K-AKT-mTOR-mediated RANKL signaling, respectively. Consistent with its cytoplasmic localization, EZH2 is required for cytoskeletal dynamics during resorption by mature OCL. Thus, EZH2 exhibits complex roles in supporting osteoclast differentiation and function.
© 2019 American Society for Bone and Mineral Research. © 2019 American Society for Bone and Mineral Research.

Entities:  

Keywords:  CYTOSKELETAL DYNAMICS; EPIGENETICS; EZH2; OSTEOCLAST; PI3K-AKT-mTOR SIGNALING

Mesh:

Substances:

Year:  2019        PMID: 31487061      PMCID: PMC7402427          DOI: 10.1002/jbmr.3863

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  63 in total

1.  The Ezh2 methyltransferase complex: actin up in the cytosol.

Authors:  Jeffrey C Nolz; Timothy S Gomez; Daniel D Billadeau
Journal:  Trends Cell Biol       Date:  2005-08-26       Impact factor: 20.808

2.  A model for transmission of the H3K27me3 epigenetic mark.

Authors:  Klaus H Hansen; Adrian P Bracken; Diego Pasini; Nikolaj Dietrich; Simmi S Gehani; Astrid Monrad; Juri Rappsilber; Mads Lerdrup; Kristian Helin
Journal:  Nat Cell Biol       Date:  2008-10-19       Impact factor: 28.824

3.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.

Authors:  Michael T McCabe; Heidi M Ott; Gopinath Ganji; Susan Korenchuk; Christine Thompson; Glenn S Van Aller; Yan Liu; Alan P Graves; Anthony Della Pietra; Elsie Diaz; Louis V LaFrance; Mark Mellinger; Celine Duquenne; Xinrong Tian; Ryan G Kruger; Charles F McHugh; Martin Brandt; William H Miller; Dashyant Dhanak; Sharad K Verma; Peter J Tummino; Caretha L Creasy
Journal:  Nature       Date:  2012-10-10       Impact factor: 49.962

4.  Global epigenomic analysis indicates protocadherin-7 activates osteoclastogenesis by promoting cell-cell fusion.

Authors:  Haruhiko Nakamura; Tomoki Nakashima; Mikihito Hayashi; Naohiro Izawa; Tetsuro Yasui; Hiroyuki Aburatani; Sakae Tanaka; Hiroshi Takayanagi
Journal:  Biochem Biophys Res Commun       Date:  2014-11-13       Impact factor: 3.575

5.  The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cells.

Authors:  R J Bryant; S J Winder; S S Cross; F C Hamdy; V T Cunliffe
Journal:  Prostate       Date:  2008-02-15       Impact factor: 4.104

Review 6.  The Polycomb complex PRC2 and its mark in life.

Authors:  Raphaël Margueron; Danny Reinberg
Journal:  Nature       Date:  2011-01-20       Impact factor: 49.962

7.  PCI-24781 down-regulates EZH2 expression and then promotes glioma apoptosis by suppressing the PIK3K/Akt/mTOR pathway.

Authors:  Wei Zhang; Shengqing Lv; Jun Liu; Zhenle Zang; Junyi Yin; Ning An; Hui Yang; Yechun Song
Journal:  Genet Mol Biol       Date:  2014-10-21       Impact factor: 1.771

8.  p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis.

Authors:  Talha Anwar; Caroline Arellano-Garcia; James Ropa; Yu-Chih Chen; Hong Sun Kim; Euisik Yoon; Sierrah Grigsby; Venkatesha Basrur; Alexey I Nesvizhskii; Andrew Muntean; Maria E Gonzalez; Kelley M Kidwell; Zaneta Nikolovska-Coleska; Celina G Kleer
Journal:  Nat Commun       Date:  2018-07-18       Impact factor: 14.919

9.  Id1 represses osteoclast-dependent transcription and affects bone formation and hematopoiesis.

Authors:  April S Chan; Kristian K Jensen; Dimitris Skokos; Stephen Doty; Hannah K Lederman; Rosandra N Kaplan; Shahin Rafii; Stefano Rivella; David Lyden
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

10.  MMP-9 facilitates selective proteolysis of the histone H3 tail at genes necessary for proficient osteoclastogenesis.

Authors:  Kyunghwan Kim; Vasu Punj; Jin-Man Kim; Sunyoung Lee; Tobias S Ulmer; Wange Lu; Judd C Rice; Woojin An
Journal:  Genes Dev       Date:  2016-01-07       Impact factor: 11.361

View more
  6 in total

1.  Bone marrow adipogenic lineage precursors promote osteoclastogenesis in bone remodeling and pathologic bone loss.

Authors:  Wei Yu; Leilei Zhong; Lutian Yao; Yulong Wei; Tao Gui; Ziqing Li; Hyunsoo Kim; Nicholas Holdreith; Xi Jiang; Wei Tong; Nathaniel Dyment; X Sherry Liu; Shuying Yang; Yongwon Choi; Jaimo Ahn; Ling Qin
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

2.  Antenatal Corticosteroid Therapy Attenuates Angiogenesis Through Inhibiting Osteoclastogenesis in Young Mice.

Authors:  Yu Chai; Jianwen Su; Weisheng Hong; Runjiu Zhu; Caiyu Cheng; Lei Wang; Xianrong Zhang; Bin Yu
Journal:  Front Cell Dev Biol       Date:  2020-12-15

3.  DZNep promotes mouse bone defect healing via enhancing both osteogenesis and osteoclastogenesis.

Authors:  Xiankun Cao; Wenxin He; Kewei Rong; Shenggui Xu; Zhiqian Chen; Yuwei Liang; Shuai Han; Yifan Zhou; Xiao Yang; Hui Ma; An Qin; Jie Zhao
Journal:  Stem Cell Res Ther       Date:  2021-12-20       Impact factor: 6.832

4.  Knockout and Double Knockout of Cathepsin K and Mmp9 reveals a novel function of Cathepsin K as a regulator of osteoclast gene expression and bone homeostasis.

Authors:  Guochun Zhu; Wei Chen; Chen-Yi Tang; Abigail McVicar; Diep Edwards; Jinwen Wang; Matthew McConnell; Shuying Yang; Yang Li; Zhijie Chang; Yi-Ping Li
Journal:  Int J Biol Sci       Date:  2022-08-29       Impact factor: 10.750

Review 5.  Epigenetic Regulators Involved in Osteoclast Differentiation.

Authors:  Kristina Astleford; Emily Campbell; Andrew Norton; Kim C Mansky
Journal:  Int J Mol Sci       Date:  2020-09-25       Impact factor: 5.923

Review 6.  Osteoclast Fusion: Physiological Regulation of Multinucleation through Heterogeneity-Potential Implications for Drug Sensitivity.

Authors:  Kent Søe
Journal:  Int J Mol Sci       Date:  2020-10-19       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.